<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5552">
  <stage>Registered</stage>
  <submitdate>6/04/2010</submitdate>
  <approvaldate>6/04/2010</approvaldate>
  <nctid>NCT01099904</nctid>
  <trial_identification>
    <studytitle>A Study on the Effect of Renal Function on the Pharmacakokinetics of RO5024048 (Parent of Prodrug RO5024048) Following Multiple Oral Dose Administration of RO5024048</studytitle>
    <scientifictitle>The Effect of Renal Function on the Pharmacokinetics of RO4995855 (Parent of ProDrug RO5024048) Following Multiple Oral Dose Administration of RO5024048</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>PP21536</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Healthy Volunteer</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - RO5024048

Experimental: 1 - Normal Renal Function

Experimental: 2 - Mild Renal Impairment

Experimental: 3 - Moderate Renal Impairment


Treatment: drugs: RO5024048
multiple oral doses for 5 days

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Phrmacokinetics of RO49958855 (parent molecule) and metabolites following multiple doses of RO5024048: AUC, Cmax, Tmax T1/2, Ae, Cl</outcome>
      <timepoint>sampling days 1 and 3-11</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Effect of renal impairment on safety and tolerability: Adverse events, vital signs, ECG, laboratory parameters</outcome>
      <timepoint>Throughout study, ECG and laboratory assessments days 3, 5, 6 and 17</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  male or female adults, 18-75 years of age

          -  normal, or mildly or moderately impaired renal function (creatinine clearance &gt;/= 30
             mL/min)

          -  BMI 18-40 kg/m2

          -  stable renal function

          -  agree to abstain from alcohol consumption during study drug adminsitration and limit
             consumption up to the end of the study

          -  agree to abstain from coffein consumption throughout study</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  positive urine or blood test for drugs of abuse not under a physician's prescription

          -  positive for HIV or HCV, or HBV with clinical symptoms or history of hepatitis

          -  uncontrolled hypertension

          -  renal transplant, dialysis patient, nephritic syndrome

          -  clinically significant cardiovascular, central nervous system, gastrointestinal or
             liver disease or disorder</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose />
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/03/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>30</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/09/2010</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Hoffmann-La Roche</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This open-label, parallel group study will evaluate the effect of renal function on the
      pharmacokinetics of RO4995855 following multiple oral dose administration of RO5024048 and
      assess the effect of renal impairment on safety and tolerability of RO5024048. Adult males or
      females with either normal renal function or mild or moderate renal impairment will receive
      RO5024048 orally for 5 days. Target sample size is &lt;50.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01099904</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Clinical Trials</name>
      <address>Hoffmann-La Roche</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>